Previsão

O preço-alvo médio dos analistas é € 65,58 (-28,17%). A mediana é € 64,08 (-29,81%).

Comprar	9
Manter	5
Vender	0

Notícias Ir para o feed de notícias

Verona Pharma shareholders approve $10 billion acquisition by Merck, Nasdaq trading to be suspended

Verona Pharma shareholders authorized Merck’s $10 billion takeover at $107 per American Depositary Share, with completion expected after a High Court hearing on October 7. Nasdaq trading in Verona Pharma shares will be suspended on the same day and the deadline for depositary share payments is October 8. The approval follows encouraging Phase 3 ENHANCE results for Verona Pharma’s COPD drug Ohtuvayre, noted as the first novel inhaled COPD mechanism in over two decades. » Mais em finance.yahoo.com
Merck takeover drives Verona Pharma to all-time high

Verona Pharma’s ADRs rose to a record high of 106.45 USD, giving the company a market capitalization of around 9.17 billion USD. Merck plans to acquire the company at 107 USD per ADS as part of a transaction worth about 10 billion USD, expected to close in the fourth quarter of 2025 and to be financed with investment-grade bonds. Analysts subsequently adjusted valuations and cut several ratings on Verona Pharma, while the stock shows a one-year return of roughly 257% and a high liquidity ratio (Current Ratio 10.71). » Mais em de.investing.com
Verona Pharma reaches record high ahead of takeover offer from Merck

The ADRs of Verona Pharma rose to an all-time high of $105.86, driven by strong price performance (up 306.73% in 12 months) and solid financial metrics. Merck has announced it will acquire Verona for $107 per ADS in a roughly $10 billion transaction, expected to close in Q4 2025. Several analysts adjusted their ratings on Verona after the takeover announcement—some downgraded the stock, while TD Cowen raised its price target to $107. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Verona Pharma ADR registou receitas de € 63,75 mi e um ganho líquido de € 7,37 mi

(EUR)	junho de 2025	YoY
Receitas	63,75 mi	-
Ganho bruto	60,81 mi	-
Ganho líquido	7,37 mi	-
EBITDA	8,41 mi	-

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 62,94 bi
Número de ações	679,83 mi
Máximo/mínimo de 52 semanas	€ 92,60 - € 26,92
Dividendos	Não
Beta	0,05
PER (PE Ratio)	-2.155,44
PEG (PEG Ratio)	-237,84
P/VC (PB Ratio)	32,90
P/V (PS Ratio)	541,71

Perfil da empresa

Verona Pharma plc, ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung und Vermarktung von Therapien für die Behandlung von Atemwegserkrankungen mit ungedecktem medizinischen Bedarf. Der Produktkandidat des Unternehmens ist Enzifentrin, ein inhalativer und dualer Inhibitor der Enzyme Phosphodiesterase (PDE) 3 und PDE4, der in einem einzigen Präparat sowohl bronchienerweiternd als auch entzündungshemmend wirkt und sich in klinischen Studien der Phase 3 zur Behandlung von chronisch obstruktiver Lungenerkrankung, Asthma und Mukoviszidose befindet. Das Unternehmen entwickelt Enzifentrin in drei Formulierungen, darunter ein Vernebler, ein Trockenpulverinhalator und ein Druckinhalator mit Dosierfunktion. Verona Pharma plc wurde im Jahr 2005 gegründet und hat seinen Hauptsitz in London, Vereinigtes Königreich.

Nome	Verona Pharma ADR
CEO	David S. Zaccardelli
Sede	London, Reino Unido
Site	veronapharma.com
Setor	Cuidados de saúde
Indústria	Produtos farmacêuticos
Entrada em bolsa	28/04/2017
Colaboradores	209